The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Aug. 13, 2015
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Kannan Rangaramanujam, Highland, MD (US);

Betty M. Tyler, Baltimore, MD (US);

Fan Zhang, Baltimore, MD (US);

Panagiotis Mastorakos, Charlottesville, VA (US);

Manoj K. Mishra, Ellicott City, MD (US);

Antonella Mangraviti, Baltimore, MD (US);

Assignee:

THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61K 31/4439 (2006.01); A61K 47/59 (2017.01); A61K 31/551 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 31/4439 (2013.01); A61K 31/551 (2013.01); A61K 47/595 (2017.08); A61K 49/0032 (2013.01); A61K 49/0054 (2013.01);
Abstract

A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier ('BBB') of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.


Find Patent Forward Citations

Loading…